In plain English
Johnson & Johnson makes pharmaceuticals, medical devices, and consumer health products for a global customer base. The company is a…
Company stock · NYSE · USD
JNJ
Johnson & Johnson
—
Price unavailable — company details still show below
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Size
- Large company
- Market value
- $635.1 billion
- Number of shares
- 2.41 billion
- Country
- US
- Went public
- Sep 25, 1944
- Exchange
- NYSE
- Website
- jnj.com
Themes
Price chart Pro
Loading chart…
Loading chart…
Company briefing
What JNJ is
Plain English context — why the name shows up in the news, and what to watch next.
Latest on this name
Insights & deeper context
24 recent cards — open any for the full deeper dive.
Johnson & Johnson Announces Data From Its VARIPURE, Omny-IRE Trials Demonstrated 100% Of Participants Had Acute Procedural Success; Mean Ablation Rate Of 17.9 Minutes Observed
In brief
JNJ’s new trial data shows a 100% success rate and very low complications, reinforcing the device’s safety and efficiency.
Johnson & Johnson Announces 1-Yr Results From Phase 3 FUZION Study Showing TREMFYA Maintained Or Improved Fistula Remission Through 48 Weeks In Adults With Crohn's Disease
In brief
TREMFYA maintains or improves fistula remission through 48 weeks, with the 100 mg dose showing a 7‑point lift from Week 24 to Week 48.
Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts
In brief
JNJ’s solid Q3 results and modest guidance lift are outweighed by analyst concerns that the company’s growth is driven by legacy drugs, setting a cautious tone for the pharma sector.
These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results
In brief
JNJ beat earnings estimates and raised guidance, but analysts trimmed price targets, leading to a modest share price gain.
Johnson & Johnson Tops Q3 Estimates, Raises 2026 Outlook on Cancer Drug Strength (UPDATED)
In brief
JNJ beats Q3 earnings, lifts guidance, but faces significant charges from litigation and acquisitions that will weigh on 2027 earnings.
Transcript: Johnson & Johnson Q3 2026 Earnings Conference Call
In brief
J&J lifts 2026 revenue outlook to $100.7 billion and signals a strong path to $50 billion oncology sales by 2030, while legal costs and integration expenses weigh on earnings.
Dow Jones Industrial Average Gets Spotlight: 5 Earnings Reports Representing 25% of ETF’s Assets On Deck
In brief
The week’s earnings from five major Dow components—worth 25.74% of DIA—will be a key driver of market volatility and could reshape the ETF’s performance.
Johnson & Johnson Announces Two-year Data From Its Phase 3 ICONIC-TOTAL Study Of ICOTYDE On High-Impact Plaque Psoriasis Sites; 60% Of Patients With Scalp Psoriasis And 89% With Genital Psoriasis Achieved Site-Specific Complete Skin Clearance At Week 112
In brief
ICOTYDE shows durable, high‑impact psoriasis clearance over two years, reinforcing its therapeutic value and market position.
Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
In brief
JNJ’s Q3 earnings are expected to dip slightly, but rising analyst targets and positive drug data may cushion the impact on the stock.
Johnson & Johnson Q3 Preview: Analyst Projects In-Line Sales, Earnings Miss
In brief
Johnson & Johnson (NYSE: JNJ) is set to report Q3 FY2027 results on Nov.
Johnson & Johnson Clinical Trials Show Progress Across Key Therapies
In brief
Positive clinical data for Tremfya and Carvykti could boost JNJ’s pipeline prospects and support future revenue growth.
Johnson & Johnson Announces That TREMFYA Met Primary And Major Secondary Endpoints Demonstrating Both Improvement In Axial Symptoms And Reduction In Inflammation By MRI Assessment In The Phase 4 STAR Study Evaluating Biologic-Naïve Adults With Active Psoriatic Arthritis And Axial Involvement
In brief
TREMFYA’s STAR trial confirms it works for axial psoriatic arthritis, boosting its therapeutic profile and market prospects.
Johnson & Johnson Announces Data From Phase 3 MajesTEC-3 Trial Demonstrates Disease Control, Survival With TECVAYLI Plus DARZALEX FASPRO To Treat Relapsed Or Refractory Multiple Myeloma
In brief
JNJ’s latest MajesTEC‑3 results reinforce its leadership in multiple myeloma treatment and may pave the way for a new frontline therapy.
Johnson & Johnson Drug Shows Improved Mania Symptoms in Bipolar Patients
In brief
Caplyta’s Phase 3 success signals a promising new treatment for acute bipolar mania, potentially boosting JNJ’s earnings and market position in psychopharmacology.
Johnson & Johnson Announces CAPLYTA Demonstrates Reduction In Signs, Symptoms Of Acute Manic Episodes Associated With Bipolar I Disorder In Phase 3 Trial
In brief
CAPLYTA’s Phase 3 success could pave the way for the first approved drug for acute manic episodes, enhancing JNJ’s neuropsychiatry pipeline.
Senator Bets on Small Cap Stocks Ahead of Likely Rate Hike: Why That Could be Risky
In brief
Boozman’s small‑cap tilt before a Fed hike could backfire if borrowing costs spike, weighing on growth‑heavy stocks.
Johnson & Johnson Says Lung Cancer Drug Shows Reduced Side Effects and Longer Patient Survival
In brief
JNJ’s new data show RYBREVANT is safer when given subcutaneously and more effective in a tough NSCLC subgroup, but the market remains wary.
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
In brief
CTNM shares slid sharply after its Phase 2 depression trial failed to meet the primary endpoint, casting doubt on the drug’s future and impacting both companies’ outlooks.
Contineum’s Phase 2 MOONLIGHT-1 Trial Of JNJ-5120/PIPE-307 Did Not Meet Its Primary Efficacy Endpoint; Analyses Of The Data, Including Prespecified Exploratory Endpoints, Are Ongoing
In brief
The MOONLIGHT‑1 trial did not meet its main goal, raising questions about JNJ‑5120/PIPE‑307’s clinical promise.
Johnson & Johnson Receives CE Marking For ACUVUE OASYS MAX 2-Week, New Reusable Contact Lens Featuring Proprietary MAX Technologies To Deliver Lasting Comfort And Clear Vision, Even At Day 14
In brief
JNJ’s new 2‑week reusable lens clears European regulators, positioning it to capture a larger share of the growing reusable‑lens market.
Timothy Schmid Exercises Options, Realizes $4.39M
In brief
Schmid’s $4.39 million option exercise adds fresh supply to JNJ shares and may dampen short‑term price momentum.
Johnson & Johnson Secures FDA Approval For First Rare Anemia Treatment
In brief
FDA clears JNJ’s first targeted therapy for a rare anemia, opening a new revenue stream and improving treatment options.
Johnson & Johnson Expands Robotic Bronchoscopy Push With AI, 3D Navigation Upgrade
In brief
JNJ’s MONARCH QUEST 3 upgrade, cleared today, adds AI and broader imaging support, positioning the company for stronger growth in robotic bronchoscopy.
EVP At Johnson & Johnson Exercises Options Worth $2.38M
In brief
JNJ insider Taubert exercised $2.38 million worth of options, underscoring management confidence in the stock.
Company reports
Official filings (US SEC and linked cards)
No filings here yet
Official report cards for JNJ will show up here when available.
Broad market indexes (like the S&P 500, a basket of 500 large US companies) are shown through popular funds that track them (for example SPY). Company profile and prices use live market data when available.